8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 7, 2026·SEC
Rockwell Medical, Inc.(RMTI)Earnings, Financials & Key Ratios
RMTI•NASDAQ
Price updated Jun 19, 2026
AboutRockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.Show more
- Revenue$69M-31.8%
- EBITDA-$2M-189.6%
- Net Income-$5M-1007.1%
- EPS (Diluted)-0.15-495.2%
- Gross Margin16.89%-2.0%
- EBITDA Margin-3.61%-231.3%
- Operating Margin-6.77%-1230.6%
- Net Margin-7.67%-1522.2%
- ROE-15.28%-757.4%
RMTI Key Insights
Rockwell Medical, Inc. (RMTI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 29.7%
- ✓Trading at only 0.6x book value
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 15.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RMTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RMTI Price & Volume
Rockwell Medical, Inc. (RMTI) stock price & volume — 10-year historical chart
Loading chart...
RMTI Growth Metrics
Rockwell Medical, Inc. (RMTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.27%
5 Years2.17%
3 Years-1.65%
TTM17690.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-609293.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1959.72%
Return on Capital
10 Years-45.01%
5 Years-30.84%
3 Years-9.77%
Last Year-10.12%
RMTI Recent Earnings
Rockwell Medical, Inc. (RMTI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.04-300.0%
$0.01
Rev
$17.3B-3.4%
$18.0B
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.01-125.0%
$0.04
Rev
$18M-1.4%
$19M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.05-25.0%
$0.04
Rev
$16M-14.3%
$19M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.05+0.0%
$0.05
Rev
$16M-1.6%
$16M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.04vs $0.01-300.0% | $17.3Bvs $18.0B-3.4% |
| Q2 2026 | Mar 26, 2026 | $0.01vs $0.04-125.0% | $18Mvs $19M-1.4% |
| Q4 2025 | Nov 12, 2025 | $0.05vs $0.04-25.0% | $16Mvs $19M-14.3% |
| Q3 2025 | Aug 14, 2025 | $0.05vs $0.05+0.0% | $16Mvs $16M-1.6% |
Based on last 12 quarters of dataView full earnings history →
RMTI Peer Comparison
Rockwell Medical, Inc. (RMTI) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 LXRX | 892.83M | 2.01 | -14.36 | 60.24% | -37.46% | -18.64% | 0.58 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 DVA | 13.35B | 207.91 | 21.86 | 6.46% | 5.65% | 59.11% | 12.99 | |
 FMC | 1.44B | 11.55 | -0.65 | -18.34% | -72.93% | -82.27% | 2.00 | |
 NXST | 5.01B | 164.16 | 54.72 | -8.47% | 3.23% | 7.53% | 3.33 |
Compare RMTI vs Peers
Rockwell Medical, Inc. (RMTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RMTI Income Statement
Rockwell Medical, Inc. (RMTI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 57.3M | 63.39M | 61.3M | 62.2M | 61.93M | 72.81M | 83.61M | 101.49M | 69.26M | 17.39B |
Revenue Growth % | 7.54% | 10.63% | -3.29% | 1.46% | -0.43% | 17.57% | 14.84% | 21.38% | -31.76% | 17690.73% |
Cost of Goods Sold | 53.6M | 64.97M | 58.46M | 59.47M | 64.35M | 68.73M | 74.91M | 84M | 57.56M | 14.48B |
COGS % of Revenue | 93.54% | 102.5% | 95.37% | 95.62% | 103.91% | 94.4% | 89.59% | 82.77% | 83.11% | - |
Gross Profit | 3.7M▲ 0% | -1.58M▼ 142.8% | 2.84M▲ 279.2% | 2.73M▼ 4.0% | -2.42M▼ 188.8% | 4.08M▲ 268.5% | 8.7M▲ 113.5% | 17.48M▲ 100.9% | 11.7M▼ 33.1% | 2.91B▲ 0% |
Gross Margin % | 6.46% | -2.5% | 4.63% | 4.38% | -3.91% | 5.6% | 10.41% | 17.23% | 16.89% | 16.71% |
Gross Profit Growth % | -45.18% | -142.8% | 279.17% | -4.01% | -188.81% | 268.47% | 113.49% | 100.87% | -33.11% | - |
Operating Expenses | 29.62M | 29.82M | 36.93M | 31.14M | 27.92M | 20.86M | 15.37M | 16.88M | 16.39M | 4.39B |
OpEx % of Revenue | 51.7% | 47.05% | 60.25% | 50.07% | 45.08% | 28.65% | 18.39% | 16.63% | 23.66% | - |
Selling, General & Admin | 23.3M | 23.08M | 30.05M | 24.05M | 21.08M | 17.74M | 14.27M | 16.86M | 16.39B | 4.39B |
SG&A % of Revenue | 40.67% | 36.41% | 49.02% | 38.67% | 34.04% | 24.36% | 17.06% | 16.61% | 23659.36% | - |
Research & Development | 6.32M | 6.74M | 6.89M | 7.09M | 6.83M | 3.12M | 1.11M | 19K | 0 | 0 |
R&D % of Revenue | 11.03% | 10.64% | 11.23% | 11.4% | 11.04% | 4.28% | 1.32% | 0.02% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16.37B | 0 |
Operating Income | -25.92M▲ 0% | -32.44M▼ 25.1% | -34.1M▼ 5.1% | -28.42M▲ 16.6% | -30.34M▼ 6.7% | -16.78M▲ 44.7% | -6.67M▲ 60.3% | 608K▲ 109.1% | -4.69M▼ 871.5% | -1.48B▲ 0% |
Operating Margin % | -45.24% | -51.18% | -55.62% | -45.69% | -48.98% | -23.05% | -7.98% | 0.6% | -6.77% | -8.53% |
Operating Income Growth % | -28.28% | -25.14% | -5.11% | 16.65% | -6.74% | 44.69% | 60.25% | 109.12% | -871.55% | - |
EBITDA | -25.41M | -31.79M | -31.44M | -26.13M | -27.82M | -16.2M | -5.23M | 2.79M | -2.5M | -1.48B |
EBITDA Margin % | -44.34% | -50.15% | -51.29% | -42.01% | -44.92% | -22.26% | -6.25% | 2.75% | -3.61% | -8.52% |
EBITDA Growth % | -30.66% | -25.11% | 1.09% | 16.89% | -6.47% | 41.76% | 67.75% | 153.35% | -189.63% | -54056.66% |
D&A (Non-Cash Add-back) | 514.36K | 650.14K | 2.65M | 2.29M | 2.52M | 576K | 1.44M | 2.18M | 2.19M | 1.68M |
EBIT | -25.92M | -31.41M | -34.1M | -29.01M | -30.31M | -16.74M | -6.14M | 774K | -4.69M | -1.48B |
Net Interest Income | 790.23K | 535.64K | 367K | -1.64M | -2.34M | -1.9M | -2.09M | -1.16M | -890K | -924K |
Interest Income | 790.23K | 535.33K | 367.08K | 238K | 22K | 33K | 211K | 92K | 234K | 205K |
Interest Expense | 0 | 0 | 0 | 1.88M | 2.36M | 1.94M | 2.3M | 1.25M | 1.12M | 1.13M |
Other Income/Expense | 1.63K | -716.7K | -3.08M | -2.47M | -2.34M | -1.9M | -1.77M | -1.09M | -623K | -125.47M |
Pretax Income | -25.92M▲ 0% | -32.13M▼ 23.9% | -37.18M▼ 15.7% | -30.89M▲ 16.9% | -32.67M▼ 5.8% | -18.68M▲ 42.8% | -8.44M▲ 54.8% | -480K▲ 94.3% | -5.31M▼ 1007.1% | -1.61B▲ 0% |
Pretax Margin % | -45.24% | -50.68% | -60.65% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.67% | -9.25% |
Income Tax | -1.63K | 313.3K | -3.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.01% | -0.98% | 8.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -25.92M▲ 0% | -32.13M▼ 23.9% | -34.13M▼ 6.2% | -30.89M▲ 9.5% | -32.67M▼ 5.8% | -18.68M▲ 42.8% | -8.44M▲ 54.8% | -480K▲ 94.3% | -5.31M▼ 1007.1% | -1.61B▲ 0% |
Net Margin % | -45.24% | -50.68% | -55.67% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.67% | -9.25% |
Net Income Growth % | -30.9% | -23.94% | -6.23% | 9.49% | -5.78% | 42.83% | 54.82% | 94.31% | -1007.08% | -609293.56% |
Net Income (Continuing) | -25.92M | -32.13M | -34.13M | -30.89M | -32.67M | -18.68M | -8.44M | -480K | -5.31M | -1.61B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.61▲ 0% | -6.69▼ 19.3% | -5.61▲ 16.1% | -4.49▲ 20.0% | -3.83▲ 14.7% | -1.89▲ 50.7% | -0.36▲ 81.0% | -0.03▲ 93.0% | -0.15▼ 495.2% | -40.81▲ 0% |
EPS Growth % | -30.77% | -19.25% | 16.14% | 19.96% | 14.7% | 50.65% | 80.95% | 93% | -495.24% | -1959.72% |
EPS (Basic) | -5.61 | -6.69 | -5.61 | -4.49 | -3.83 | -1.89 | -0.36 | -0.03 | -0.15 | - |
Diluted Shares Outstanding | 4.62M | 4.8M | 5.54M | 6.87M | 8.53M | 9.87M | 23.32M | 31.06M | 35.97M | 39.42M |
Basic Shares Outstanding | 4.62M | 4.8M | 5.54M | 6.87M | 8.53M | 9.87M | 23.32M | 31.06M | 35.97M | 39.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RMTI Balance Sheet
Rockwell Medical, Inc. (RMTI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 48.83M | 46.83M | 36.87M | 69.47M | 35.29M | 35.31M | 28.77M | 37.03M | 38.16M | 36.94M |
Cash & Short-Term Investments | 33.06M | 33.53M | 26.05M | 58.68M | 22.44M | 21.49M | 10.94M | 21.6M | 21.6M | 23.89M |
Cash Only | 8.41M | 22.71M | 11.79M | 48.68M | 13.28M | 10.1M | 8.98M | 15.66M | 15.66M | 9.61M |
Short-Term Investments | 24.65M | 10.82M | 14.25M | 10M | 9.16M | 11.39M | 1.95M | 5.94M | 14.29M | 14.28M |
Accounts Receivable | 6.36M | 7.35M | 4.2M | 4.17M | 5.91M | 6.26M | 10.9M | 8.29M | 8.14M | 8.82M |
Days Sales Outstanding | 40.48 | 42.33 | 25.02 | 24.48 | 34.85 | 31.38 | 47.59 | 29.82 | 42.91 | 0.18 |
Inventory | 7.64M | 4.04M | 3.65M | 3.91M | 4.08M | 5.81M | 5.87M | 5.78M | 3.42M | 3.06M |
Days Inventory Outstanding | 52.01 | 22.69 | 22.77 | 24.02 | 23.12 | 30.87 | 28.61 | 25.11 | 21.71 | 0.07 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.75M | 1.06M | 1.36M | -24.97B | 1.17M |
Total Non-Current Assets | 9.95M | 5.73M | 7.44M | 8.28M | 13.29M | 11.32M | 23.4M | 22.18M | 18.98M | 20.48M |
Property, Plant & Equipment | 2.55M | 2.64M | 5.65M | 5.55M | 10.22M | 8.61M | 11.02M | 10.34M | 0 | 9.48M |
Fixed Asset Turnover | 22.48x | 24.03x | 10.86x | 11.20x | 6.06x | 8.46x | 7.59x | 9.81x | - | 2503.07x |
Goodwill | 920.75K | 920.75K | 921K | 921K | 921K | 921K | 921K | 921K | 921K | 921K |
Intangible Assets | 4.03K | 0 | 0 | 0 | 0 | 0 | 10.76M | 10.21M | 9.66M | 9.52M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 6.48M | 2.17M | 876K | 1.8M | 2.14M | 1.8M | 705K | 706K | 8.4M | 556K |
Total Assets | 58.78M▲ 0% | 52.56M▼ 10.6% | 44.32M▼ 15.7% | 77.75M▲ 75.4% | 48.57M▼ 37.5% | 46.63M▼ 4.0% | 52.17M▲ 11.9% | 59.21M▲ 13.5% | 57.15M▼ 3.5% | 57.42M▲ 0% |
Asset Turnover | 0.97x | 1.21x | 1.38x | 0.80x | 1.27x | 1.56x | 1.60x | 1.71x | 1.21x | 309.53x |
Asset Growth % | -29.31% | -10.59% | -15.68% | 75.44% | -37.52% | -3.99% | 11.88% | 13.48% | -3.48% | 2.88% |
Total Current Liabilities | 9.14M | 13.2M | 12.37M | 12.79M | 20.97M | 17.69M | 16.64M | 14.09M | 9.58M | 9.87M |
Accounts Payable | 4.22M | 4.49M | 3.02M | 4.16M | 3.74M | 4.05M | 4.52M | 2.87M | 2M | 3.45M |
Days Payables Outstanding | 28.75 | 25.24 | 18.84 | 25.5 | 21.21 | 21.52 | 22 | 12.47 | 12.68 | 0.05 |
Short-Term Debt | 0 | 0 | 763K | 0 | 7.82M | 2.13M | 244K | 268K | 264K | 2.69M |
Deferred Revenue (Current) | 205.3K | 2.32M | 2.29M | 2.33M | 2.31M | 1.8M | 289K | 143K | 0 | 314K |
Other Current Liabilities | 1.99M | 2.38M | 1.49M | 3.03M | 2.17M | 2.87M | 5.17M | 5.29M | 5.69M | 2.31M |
Current Ratio | 5.34x | 3.55x | 2.98x | 5.43x | 1.68x | 2.00x | 1.73x | 2.63x | 3.98x | 3.74x |
Quick Ratio | 4.51x | 3.24x | 2.69x | 5.12x | 1.49x | 1.67x | 1.38x | 2.22x | 3.63x | 3.43x |
Cash Conversion Cycle | 63.74 | 39.78 | 28.95 | 22.99 | 36.76 | 40.73 | 54.19 | 42.46 | 51.95 | 0.19 |
Total Non-Current Liabilities | 16.72M | 12.08M | 11.62M | 30.79M | 25.07M | 14.84M | 14.24M | 12.53M | 10.58M | 11.7M |
Long-Term Debt | 0 | 0 | 0 | 20.95M | 13.19M | 7.55M | 8.29M | 8.47M | 8.83M | 8.21M |
Capital Lease Obligations | 0 | 0 | 1.78M | 1.82M | 5.89M | 4.67M | 2.96M | 2.63M | 1.76M | 10.02M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 14K | 14K | 2.51M | 1M | 0 | 0 |
Total Liabilities | 25.87M | 25.28M | 24M | 43.58M | 46.04M | 32.53M | 30.88M | 26.62M | 20.16M | 21.57M |
Total Debt | 0 | 0 | 4.04M | 23.94M | 28.89M | 16.36M | 13.44M | 13.54M | 12.47M | 14.39M |
Net Debt | -8.41M | -22.71M | -7.76M | -24.75M | 15.62M | 6.26M | 4.46M | -2.13M | -3.19M | 4.78M |
Debt / Equity | - | - | 0.20x | 0.70x | 11.40x | 1.16x | 0.63x | 0.42x | 0.34x | 0.40x |
Debt / EBITDA | - | - | - | - | - | - | - | 4.85x | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.76x | - | -0.00x |
Interest Coverage | - | - | - | -15.44x | -12.84x | -8.65x | -2.67x | 0.62x | -4.17x | -1313.51x |
Total Equity | 32.91M▲ 0% | 27.28M▼ 17.1% | 20.32M▼ 25.5% | 34.17M▲ 68.2% | 2.54M▼ 92.6% | 14.11M▲ 456.4% | 21.29M▲ 50.9% | 32.59M▲ 53.1% | 36.98M▲ 13.5% | 35.86M▲ 0% |
Equity Growth % | -37.85% | -17.12% | -25.5% | 68.16% | -92.58% | 456.45% | 50.94% | 53.05% | 13.49% | 83.71% |
Book Value per Share | 7.12 | 5.68 | 3.67 | 4.97 | 0.30 | 1.43 | 0.91 | 1.05 | 1.03 | 0.91 |
Total Shareholders' Equity | 32.91M | 27.28M | 20.32M | 34.17M | 2.54M | 14.11M | 21.29M | 32.59M | 36.98M | 35.86M |
Common Stock | 273.21M | 5.7K | 7K | 9K | 1K | 1K | 3K | 3K | 4K | 4K |
Retained Earnings | -240.26M | -272.39M | -306.52M | -337.41M | -370.08M | -388.76M | -397.2M | -397.68M | -402.99M | -404.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -35.38K | 63.15K | 52K | 57K | 52K | 163K | -1K | 54K | 131K | 133K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RMTI Cash Flow Statement
Rockwell Medical, Inc. (RMTI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -21.11M | -20.42M | -27.25M | -29.64M | -33.53M | -16.93M | -9.41M | 4.2M | -659K | 2.66M |
Operating CF Margin % | -36.85% | -32.21% | -44.46% | -47.66% | -54.15% | -23.25% | -11.26% | 4.14% | -0.95% | - |
Operating CF Growth % | -69.56% | 3.29% | -33.47% | -8.76% | -13.13% | 49.52% | 44.4% | 144.65% | -115.68% | 157.37% |
Net Income | -25.92M | -32.13M | -34.13M | -30.89M | -32.67M | -18.68M | -8.44M | -480K | -5.31M | -1.61B |
Depreciation & Amortization | 514.36K | 650.14K | 2.65M | 2.29M | 2.52M | 576K | 1.44M | 2.18M | 2.19M | 2.16M |
Stock-Based Compensation | 7.17M | 4.39M | 4.95M | 475K | 943K | 315K | 932K | 1.29M | 1.82M | 914K |
Deferred Taxes | 0 | 9M | 0 | 0 | 156K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 802.98K | 1.1M | 1.24M | 1.44M | 369K | 2.98M | 3.9M | 2.74M | 2.26M | 3.07M |
Working Capital Changes | -3.68M | -3.43M | -1.98M | -2.96M | -4.84M | -2.13M | -7.24M | -1.53M | -1.61M | 1.92M |
Change in Receivables | -962.34K | -623.95K | 2.78M | 32K | -1.74M | -346K | -4.64M | 2.61M | -98K | 599K |
Change in Inventory | 343.49K | -835.64K | 316.87K | -1.31M | -656K | -2.1M | 1.18M | -332K | 2.78M | 2.42M |
Change in Payables | -1.64M | 269.91K | -1.47M | 1.14M | -416K | 314K | 463K | -1.65M | -870K | 1.52M |
Cash from Investing | 14.5M | 12.72M | -4.75M | 3.21M | 311K | -2.4M | -3.04M | -4.87M | -8.54M | -8.66M |
Capital Expenditures | -1.68M | -994.26K | -1.34M | -1.05M | -522K | -281K | -284K | -1.01M | -542K | -904K |
CapEx % of Revenue | 2.94% | 1.57% | 2.18% | 1.68% | 0.84% | 0.39% | 0.34% | 1% | 0.78% | 0.01% |
Acquisitions | 725 | -250K | 750K | 0 | -833K | 0 | -12.36M | 0 | 0 | 175K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 725 | 250.4K | -750K | 0 | 833K | 0 | 0 | 0 | 190K | 0 |
Cash from Financing | -2.16M | 22M | 21.08M | 63.32M | -2.18M | 16.15M | 11.34M | 7.35M | 4.25M | 4.22M |
Debt Issued (Net) | 0 | 0 | -1.15M | 21.74M | -2.28M | -13.68M | -3.51M | -1.2M | -1.19M | -1.16M |
Equity Issued (Net) | 123.6K | 22M | 23.88M | 45.45M | 107K | 30.02M | 14.86M | 10.18M | 7.82M | 7.82M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -2.29M | 0 | -279K | -19K | -6K | 0 | 0 | 0 | 0 | 0 |
Other Financing | -2.29M | 3.5K | -1.65M | -3.88M | -6K | -191K | -5K | -1.63M | -2.37M | -2.44M |
Net Change in Cash | -8.77M▲ 0% | 14.31M▲ 263.1% | -10.92M▼ 176.3% | 36.89M▲ 437.8% | -35.4M▼ 196.0% | -3.18M▲ 91.0% | -1.12M▲ 64.8% | 6.68M▲ 696.9% | -4.95M▼ 174.1% | -1.78M▲ 0% |
Free Cash Flow | -22.8M▲ 0% | -21.41M▲ 6.1% | -28.59M▼ 33.5% | -30.69M▼ 7.3% | -34.06M▼ 11.0% | -17.21M▲ 49.5% | -9.7M▲ 43.7% | 3.19M▲ 132.9% | -1.2M▼ 137.6% | 1.76M▲ 0% |
FCF Margin % | -39.79% | -33.78% | -46.64% | -49.34% | -54.99% | -23.64% | -11.6% | 3.14% | -1.73% | 0.01% |
FCF Growth % | -77.99% | 6.07% | -33.52% | -7.33% | -10.98% | 49.47% | 43.66% | 132.91% | -137.64% | -18.66% |
FCF per Share | -4.93 | -4.46 | -5.16 | -4.46 | -3.99 | -1.74 | -0.42 | 0.10 | -0.03 | 0.04 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.64x | 0.80x | 0.96x | 1.03x | 0.91x | 1.12x | -8.75x | 0.12x | -0.00x |
Interest Paid | 0 | 0 | 0 | 1.56M | 0 | 1.47M | 1.21M | 847K | 0 | 190K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RMTI Key Ratios
Rockwell Medical, Inc. (RMTI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -60.37% | -106.75% | -143.4% | -113.38% | -178.04% | -224.49% | -47.68% | -1.78% | -15.28% | -4587.82% |
Return on Invested Capital (ROIC) | -64.5% | -167.39% | -298.65% | -193.89% | -165.02% | -65.35% | -21.7% | 1.62% | -10.95% | -3070.02% |
Gross Margin | 6.46% | -2.5% | 4.63% | 4.38% | -3.91% | 5.6% | 10.41% | 17.23% | 16.89% | 16.71% |
Net Margin | -45.24% | -50.68% | -55.67% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.67% | -9.25% |
Debt / Equity | - | - | 0.20x | 0.70x | 11.40x | 1.16x | 0.63x | 0.42x | 0.34x | 0.40x |
Interest Coverage | - | - | - | -15.44x | -12.84x | -8.65x | -2.67x | 0.62x | -4.17x | -1313.51x |
FCF Conversion | 0.81x | 0.64x | 0.80x | 0.96x | 1.03x | 0.91x | 1.12x | -8.75x | 0.12x | -0.00x |
Revenue Growth | 7.54% | 10.63% | -3.29% | 1.46% | -0.43% | 17.57% | 14.84% | 21.38% | -31.76% | 17690.73% |
Related:RMTI Dividend History·RMTI Revenue History·RMTI Price History·RMTI P/E History·RMTI Financial Ratios·RMTI Institutional Holders
RMTI SEC Filings & Documents
Rockwell Medical, Inc. (RMTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
RMTI Frequently Asked Questions
Rockwell Medical, Inc. (RMTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rockwell Medical, Inc. (RMTI) reported $17.39B in revenue for fiscal year 2025. This represents a 526759% increase from $3.3M in 1997.
Rockwell Medical, Inc. (RMTI) saw revenue decline by 31.8% over the past year.
Rockwell Medical, Inc. (RMTI) reported a net loss of $1.61B for fiscal year 2025.
Dividend & Returns
Rockwell Medical, Inc. (RMTI) has a return on equity (ROE) of -15.3%. Negative ROE indicates the company is unprofitable.
Rockwell Medical, Inc. (RMTI) generated $1.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.